FUJIFILM Irvine Scientific, Inc., a provider of optimization, development and manufacture of cell culture media and industrial cell culture solutions, introduced BalanCD Gal Supplement, a new formula developed to increase galactosylation in biotherapeutic development, to help achieve desired glycan profiles for improved product quality and antibody efficacy.
 
Glycosylation is a critical aspect in development and optimization of protein-based therapeutics and can significantly affect antibody binding, function, and therapeutic efficacy. Galactosylation is a key method for controlling product quality due to the significant impact it has on antibody function, and the ability to control levels of galactosylation through the cell culture medium. 
 
BalanCD Gal Supplement is a chemically-defined, animal component-free formula designed to increase N-linked galactosylation with a scalable protocol, offering researchers a method to control the process through the cell culture medium. According to the company, the supplement is effective at low concentrations and is compatible with any basal growth medium.
  
“The BalanCD Gal Supplement has been designed to incorporate seamlessly into our BalanCD media portfolio, providing researchers in biotherapeutic development with a holistic, efficient growth and production platform. Developed by our expert research and development group, the new supplement supports scientists in streamlining workflows, ultimately to advance emerging therapies,” said Robert Newman PhD, Chief Scientific Officer, FUJIFILM Irvine Scientific.